^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Foresight CLARITY™

    Company:
    Foresight Diagnostics
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    23d
    Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, M.D. Anderson Cancer Center | Suspended --> Active, not recruiting
    Enrollment closed • Minimal residual disease
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Foresight CLARITY™
    |
    Breyanzi (lisocabtagene maraleucel)
    27d
    Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=50, Suspended, M.D. Anderson Cancer Center | N=10 --> 50
    Enrollment change • Minimal residual disease
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Foresight CLARITY™
    |
    Breyanzi (lisocabtagene maraleucel)
    29d
    Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=10, Suspended, M.D. Anderson Cancer Center | Recruiting --> Suspended
    Trial suspension • Minimal residual disease
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Foresight CLARITY™
    |
    Breyanzi (lisocabtagene maraleucel)
    2ms
    Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=10, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open • Minimal residual disease
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Foresight CLARITY™
    |
    Breyanzi (lisocabtagene maraleucel)
    3ms
    ALPHA3: Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL (clinicaltrials.gov)
    P2, N=250, Recruiting, Allogene Therapeutics | Trial completion date: Aug 2031 --> Dec 2032 | Trial primary completion date: Aug 2027 --> Dec 2027
    Trial completion date • Trial primary completion date • Minimal residual disease
    |
    Foresight CLARITY™
    |
    cyclophosphamide • fludarabine IV
    3ms
    ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=38, Not yet recruiting, Michael Spinner, MD | Trial completion date: Apr 2033 --> Oct 2033 | Initiation date: Oct 2025 --> May 2026 | Trial primary completion date: Oct 2028 --> Mar 2029
    Trial completion date • Trial initiation date • Trial primary completion date • Circulating tumor DNA
    |
    Foresight CLARITY™
    |
    Keytruda (pembrolizumab) • gemcitabine • pegylated liposomal doxorubicin • Neulasta (pegfilgrastim)
    5ms
    Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=10, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial • Minimal residual disease
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Foresight CLARITY™
    |
    Breyanzi (lisocabtagene maraleucel)
    9ms
    ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=38, Not yet recruiting, Michael Spinner, MD | Initiation date: Jul 2025 --> Oct 2025
    Trial initiation date • Circulating tumor DNA
    |
    Foresight CLARITY™
    |
    Keytruda (pembrolizumab) • gemcitabine • pegylated liposomal doxorubicin • Neulasta (pegfilgrastim)
    1year
    ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=38, Not yet recruiting, Michael Spinner, MD
    New P2 trial • Circulating tumor DNA
    |
    Foresight CLARITY™
    |
    Keytruda (pembrolizumab) • gemcitabine • pegylated liposomal doxorubicin • Neulasta (pegfilgrastim)
    1year
    QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships (Qiagen)
    "The new collaborations with Tracer Biotechnologies and Foresight Diagnostics expand QIAGEN’s reach in MRD testing and cover solid tumors and hematological cancers."
    Licensing / partnership
    |
    Foresight CLARITY™
    over1year
    Foresight Diagnostics and Leading Global Cancer Center to present new data on foresight CLARITY™ Ultra-Sensitive MRD Detection in early-stage breast cancer at the 2024 San Antonio Breast Cancer Symposium (Businesswire)
    "Foresight...announced new data from its ultra-sensitive Foresight CLARITY™ minimal residual disease (MRD) platform in early-stage breast cancer that will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS)...Foresight and Memorial Sloan Kettering (MSK) will present an analysis of 470 samples from 81 early-stage breast cancer patients demonstrating that ctDNA clearance following various perioperative treatments – including surgery, neoadjuvant chemotherapy, and adjuvant chemotherapy – is strongly associated with favorable survival outcomes."
    Clinical data
    |
    Foresight CLARITY™
    over1year
    Foresight Diagnostics to Present New Data on Foresight CLARITY Ultra-Sensitive MRD Detection Across Multiple Studies at the 66th American Society of Hematology Annual Meeting (Businesswire)
    "The presentations span various lymphoma types and treatment settings, demonstrating the broad applicability of the Foresight CLARITY MRD detection technology for monitoring treatment response and predicting patient outcomes....'We see in these studies that MRD measurement with Foresight CLARITY consistently enables earlier and more accurate treatment response assessment than conventional imaging-based methods. The ability to monitor disease status in real-time with ultra-sensitive MRD assays like Foresight CLARITY may help accelerate clinical trials and lead to more personalized decision-making for patient care'."
    Clinical data
    |
    Foresight CLARITY™